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Abstract
The increased prevalence of Clostridium difficile infection (CDI) has coincided with enhanced transmissibility and severity of
disease, which is often linked to two distinct clonal lineages designated PCR-ribotype 027 and 017 responsible for CDI
outbreaks in the USA, Europe and Asia. We assessed sporulation and susceptibility of three PCR-ribotypes; 012, 017 and 027
to four classes of disinfectants; chlorine releasing agents (CRAs), peroxygens, quaternary ammonium compounds (QAC) and
biguanides. The 017 PCR-ribotype, showed the highest sporulation frequency under these test conditions. The oxidizing
biocides and CRAs were the most efficacious in decontamination of C. difficile vegetative cells and spores, the efficacy of the
CRAs were concentration dependent irrespective of PCR-ribotype. However, there were differences observed in the
susceptibility of the PCR-ribotypes, independent of the concentrations tested for VirkonH, NewgennH, Proceine 40H and
HibiscrubH. Whereas, for Steri7H and BiocleanseH the difference observed between the disinfectants were dependent on
both PCR-ribotype and concentration. The oxidizing agent PerasafeH was consistently efficacious across all three PCR
ribotypes at varying concentrations; with a consistent five Log10 reduction in spore titre. The PCR-ribotype and
concentration dependent differences in the efficacy of the disinfectants in this study indicate that disinfectant choice is a
factor for llimiting the survival and transmission of C. difficile spores in healthcare settings.
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Introduction
Clostridium difficile-infection (CDI) is an antibiotic associated
diarrhoea, caused by C. difficile, a Gram-positive, spore-forming
anaerobic bacillus. CDI clinical symptoms can range from mild
diarrhoea to life threatening pseudomembranous colitis. Antibiotic
therapy is proposed to elicit CDI by disruption of the intestinal
microbiota, which enables colonization of the gastrointestinal
tract by indigenous or ingested C. difficile. C. difficile was first
recognized as a pathogen over 30 years ago, and primarily CDI
was associated with immune suppressed and elderly patients,
receiving antibiotic treatment [1]. However, in the last 10 years C.
difficile has emerged as a global pathogen, with epidemics across
Europe, Asia and the USA, culminating in the transcontinental
spread of ‘hypervirulent’ PCR-ribotypes [2,3,4]. Evolutionary and
genetic analysis of C. difficile have revealed five distinct clonal
lineages, Clades 1–5 inclusive, which are conserved across analysis
methods such as microarray [5], MLST sequence type (ST) [6]
and whole genome sequencing [7]. The most notable being the
PCR-ribotype 027/Clade 1/ST-1 and 017/Clade 4/ST-37,
which have brought a concomitant increase in disease severity,
mortality, recurrence rate, enhanced relative transmissibility and
decreased mean age of infection [4,8,9]. Consequently, C. difficile is
the most frequent cause of nosocomial diarrhoea worldwide
[10,11]. C. difficile has a unique advantage over other healthcare
associated communicable infections such as methicillin resistant
Staphlococcus aureus (MRSA), due to its ability to form spores, which
are central to transmission of C. difficile. Patients with C. difficile are
estimated to excrete between 1610
4 and 1610
7 spores per gram of
faeces [12,13]. Spores are highly infectious and readily transmis-
sible [13], hence they are particularly problematic in healthcare
settings [14], as they are able to persist on a variety of surfaces
[15,16,17,18] and are resistant to many disinfectants [19,20,21].
The use of disinfectants in combating the spread of CDI in
hospitals and the community is central to infection control
strategies, particularly as studies indicate a correlation between
overlapping resistance mechanisms to disinfectants, antiseptics and
antibiotics [22,23]. Adaptation to altered antibiotic treatment
regimes has been met with modified antimicrobial resistance
patterns within C. difficile isolates [24,25,26], which is particularly
apparent within the 027 lineage, whereby some 027 isolates have
acquired fluoroquinolone resistance [7].
Resistance to antibiotics and disinfectants is a potential problem
in managing infection control. There is a broad selection of
disinfectants available, with differing active compounds. Presently,
the UK Department of Health and Health Protection Agency
guidelines advocate the use of chlorine-based disinfectants at a
concentration of 1000 ppm for disinfection of C. difficile.
Representative isolates of the 012, 017 and 027 PCR-ribotypes
were chosen for analysis; strain 630 is an 012 PCR ribotype is a
virulent multidrug resistant strain isolated from an outbreak in
a Zurich hospital in 1982 [27], and was therefore isolates before
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25754may of the disinfectants in this study were manufactured. Strain
630 was the first C. difficile genome to be fully sequenced [28].
Strain R20291 is a representative 027 PCR-ribotype that was
isolated from an outbreak in Stoke Mandeville hospital in 2006
and strain M68 is a representative 017 PCR-ribotype that was
isolated from a CDI outbreak in Ireland in 2006, both of which
have been fully sequenced [7]. We tested the susceptibility
of spores and vegetative cells from the 012, 017 and 027 PCR-
ribotypes to a panel of nine commercially available biocides
from four categories of disinfectant. These include chlorine
releasing agents (CRAs), peroxygen releasing agents, quaternary
ammonium compounds (QACs), and a chlorhexidine based hand
wash.
With the exception of PerasafeH, the disinfectants fell into three
categories, i) those whose efficacy were concentration dependent,
independent of the PCR-ribotype, ii) those whose efficacy were
PCR-ribotype dependent and iii) those whose efficacies were
dependent on both PCR-ribotype and concentration. PerasafeH
was the only disinfectant consistently efficacious across all three
PCR ribotypes at varying concentrations, where survival was
below the limit of detection.
Results
Sporulation of C. difficile PCR-ribotypes
Spore production is a unique feature of C. difficile among other
important healthcare pathogens, therefore vegetative cell
production and sporulation of three representative PCR-
ribotypes 012, 017 and 027 (Figure 1a) was analysed. The 012
and 027 strains exhibited similar levels of sporulation in minimal
media, 5.7610
4 CFU/ml and 5.1610
4 CFU/ml respectively,
whereas the 017 strain spore titre was significantly higher,
1.8610
5 (p,0.0000 Partial F-test) (Figure 1b). This observation
was consistent with heat resistant spores and microscopy
counted spores (Spores were counted using a Neubauer-ruled
Bright Line counting chambers; Hausser Scientific data not
shown).
Susceptibility to disinfectants
The susceptibility of 012, 017 and 027 PCR ribotypes to a panel
of disinfectants was assessed in-vitro using pure C. difficile cultures at
2.9610
8 (60.5). Preliminary investigations were performed with
contact times of 2 minutes, 30 minutes and 4 hours. There were
no significant differences between the data obtained at these time
points, therefore a 30 minute contact was used throughout for
experimental ease. The disinfectants used in the study are listed in
Table 1. The data is expressed on a Log plot as normalized CFU/
ml to take into account the differences in spore production
between the three ribotypes. Statistical analysis (see methods) was
performed to address three questions i) is there a strain dependent
sensitivity to the disinfectants? ii) if so, what is the most appropriate
concentration to use? and iii) which disinfectant has the greatest
efficacy across all three PCR-ribotypes and concentrations?
Chlorine releasing agents
CRAs are halogenic compounds widely used in disinfection
regimes. The active ingredients in ActichlorH and HaztabH are
sodium dichloroisocyanurate (NaDCC), Adipic acid and NaDCC
respectively. The manufacturers’ recommended working concen-
trations vary slightly for outbreaks and blood spills, but are
conserved for general use (Table 1). The susceptibility of the 012,
017 and 027 ribotypes to chlorine releasing disinfectants revealed
that at 5000 ppm survival was below the limit of detection of the
assay in all ribotypes (Figure 2A and 2B), whereas at 1000 and
500 ppm, spores survived for all three ribotypes.) (Figure 2A and
2B). A Chi
2 interaction test and a partial F-test revealed that
although concentration and PCR-ribotype were linked, the
efficacy of the disinfectants were concentration dependent,
irrespective of PCR-ribotype for both ActichlorH and HazTabH
(Tables 2 and 3). Overall, there were no significant differences
between the efficacy of ActichlorH and HazTabH (Table 3).
Peroxygens
Peroxygens are oxidizing agents, two differently acting peroxy-
gens were tested, PerasafeH and VirkonH (Table 1). The efficacy of
Figure 1. Vegetative cells and Spore counts of C. difficile PCR ribotypes 012, 017 and 027. A) Total cell counts and spore counts were
obtained by plating cultures and heat resistant samples of C. difficile on blood plates containing 0.1% taurocholate. B) Percentage spore counts were
obtained by calculating the number of heat resistant spores as a proportion of the total cell counts. Data consists of three biological and two
technical replicates from separate cultures. Student T-tests were performed between total counts and spores for each strain and significant
differences are marked with a bracket * (p,0.05). A comparison for percentage survival of spores was performed using linear regression and a
partial F-test, where M68 was the reference strain, a significant difference (p,0.01) in spore production between the three strains is marked with a
bracket **.
doi:10.1371/journal.pone.0025754.g001
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rate for all PCR-ribotypes tested was below the limit of detection
when treated with PerasafeH, which was consistent across all the
concentrations tested (Figure 2C). Using a Linear regression model,
factoring for strain (PCR-ribotype), concentration and disinfectant, we
can estimate based on the coefficient of variance from the reference
ActichlorH, that PerasafeH exhibited the lowest level of survival of all
nine disinfectants under the test conditions (Table 3). Treatment with
VirkonH revealed survival was PCR-ribotype dependent (p,0.01;
Table 3), whereby survival of the 027 ribotype was significantly lower
than the 012 and 017 ribotypes (Figure 2G).
Quaternary ammonium compounds (QACs)
QAC’s are cationic surfactants, four different QACs were tested,
BiocleanseH,N e w g e n n H,P r o c e i n e - 4 0 H and Steri7H (Table 1). These
surfactants were distributed into two categories, those whose efficacies
were strain dependent irrespective of concentration (NewgennH and
Proceine-40H, Table 2) and those that were linked to both PCR-
ribotype and concentration (BiocleanseH and Steri7H,T a b l e2 ) .T h e
PCR-ribotype 027 was more susceptible to treatment with NewgennH,
Proceine-40H and Steri7H (Figure 2D, 2E and 2H), whereas the PCR-
ribotype 027 is more resistant to BiocleanseH (Table 2, Figure 2I). The
recommended working concentrations of BiocleanseH and Steri7H are
5% and 100% respectively, however, the PCR-ribotype dependent
differences indicate that for BiocleanseH the 027 ribotype is more
susceptible to 5%, whereas the 017 ribotype is more susceptible to
10%andthe012PCR-ribotypeismore susceptibleto20%(Figure2I).
For Steri7H the 027 and 012 PCR-ribotypes are more susceptible to a
concentration of 100%, whereas the PCR-ribotype 017 is more
susceptible to a concentration of 40% (Figure 2H). A low level of
survival of 012 vegetative cells was detected for Steri7H at 20%.
Biguanides
The active ingredient in Hibiscrub is chlorhexidine gluconate
(Table 1), which is widely used in hand wash. A three variant chi
2
test was performed to determine the efficacy of HibiscrubH
(Figure 2F, table 3) the 027 PCR-ribotype was significantly more
resistant to HibiscrubH than the 012 PCR-ribotype and 017 PCR-
ribotype (p,0.01) (Figure 2F).
Discussion
The efficacy of disinfectants against the nosocomial pathogen C.
difficile is central to infection control strategies, especially as
colonization rates near infected individuals are as high as 58%
[16]. Recent publications have indicated aerosolization of spores as
well as environmental contamination contribute to dissemination of
C. difficile [13]. The transmissibility and virulence of C. difficile is
continually evolving, through ecological and environmental influ-
ences. The spores produced by C. difficile enhance transmission due
to their ability to survive in the environment [18,29,30] and resists
biocides [19,20,21]. Cross resistance has been observed between
biocides and antibiotics [31,32,33,34], which is enhanced by
exposure to sub-inhibitory concentrations of biocide [35].
Weshow variation insporulation rates ofC.difficile PCR-ribotypes
012, 017 and 027. The toxin defective strain M68, an 017 PCR-
ribotype, showed the highest sporulation frequency under these test
conditions, with an average of 3.5 times the spore titre compared to
012 and 027 PCR-ribotypes. The high sporulation rate of the 017
PCR-ribotype, may have contributed to the transcontinental spread
of the 017 PCR-ribotype, in spite of their lack of one of the major
virulencefactors,toxinAfromthislineage.Limitingthetransmission
of C. difficile spores in healthcare settings is an important factor in
infection control;however,evensporicidal disinfectantsarerelatively
inactive against C.difficile spores,which areabletoremainon various
surfaces even after disinfection [36,37]. Contaminated surfaces have
been implicated as reservoirs for airborne transmission of spores,
which can be aerosolized by disturbance of these contaminated
environments [13]. The transmission of environmental spores and
efficacyofdisinfectantstopreventpatient-to-patienttransmissionhas
recently been addressed using a murine model, in which oxidizing
Table 1. The disinfectants used in this study.
Disinfectant
name Biocide type Active ingredient(s)
Recommended
concentration Recommended uses Manufacturer
ActichlorH CRA sodium dichloroisocyanurate 1000 ppm (5000 ppm*) blood and body fluid spills Ecolab
(Troclosene Sodium) and for general hygiene
BioclenseH QAC Benzalkonium chloride 5% surfaces and general hygiene Teknon
HazTabH CRA Sodium Dichloroisocyanurate 1000 ppm (10000 ppm*) blood and body fluid spills Guest Medical LTD
(Sodium dichloro-1,3,5
triazinetrione dihydrate)
and for general hygiene
HibiscrubH Cationic bis-
biguanide
chlorhexidine gluconate 100% Handwash Regent Medical
NewGennH QAC Di-decyl dimethyl ammonium
chloride
0.8% surfaces, general hygiene and
equipment
NewwGenn research
PeraSafeH Peroxygen peracetic acid 1.62% medical devices, surfaces and
general hygiene
Micro Medical
Proceine 40H QAC alkyl-amino-alkyl glycines 0.6% small spills, surfaces and general
hygiene
AGMA
Steri 7H QAC Isothiazolium-benzalkonium
chloride
100% general hygiene and surfaces Sentinal International
LTD
VirkonH Peroxygen potassium peroxymonosulfate 1% hazardous spills, surfaces and
equipment
DuPont
The active ingredients, biocide type and recommended working concentrations and recommended uses are listed. Outbreak or blood spill concentrations are
highlighted with * where they differ from the standard working concentrations. There were no minimum contact times provided for the disinfectants.
doi:10.1371/journal.pone.0025754.t001
Disinfectants and Clostridium difficile
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25754disinfectants had the most effective reduction in transmission
efficiency of the 017 PCR-ribotype strain M68 [38]. This along
with the data we present highlights the importance of disinfectant
choice in limiting the spread of CDI.
In thisstudy,with theexceptionof PerasafeH, the disinfectants fell
into three categories, i) those whose efficacies were dependent on
concentration, ii) those whose efficacy were dependent on PCR-
ribotype and iii) those whose efficacies were dependent on both
PCR-ribotype and concentration. The use of CRAs, peroxygen
based compounds, QACs and biguanides is widespread in the
hospitalsetting, with different biocides used for distinct applications,
including; antiseptic, disinfectant or preservative treatments [39].
Biocide activity can be affected by several different factors,
including; concentration, contact time, pH, temperature, organic
matter, as well as the number and condition of the bacteria, such as
vegetative cells, biofilms and spore [39]. Within our experimental
system, the tests were performed on liquid cultures to enable direct
comparisons to be made between different disinfectants. However,
some of these disinfectants are surfactants, therefore the low level of
activity of some of these compounds could be linked to the
experimental methods used. The most effective biocides across all
three PCR-ribotypestestedweretheoxidizingagents, suchasCRAs
(Specifically ActichlorH and HazTabH) and peroxygens (specifically
PerasafeH), which damage DNA, proteins and lipids [40]. It has
been shown that oxidizing agents such as H2O2 interfere with the
spore coat thusrendering the spore nonviable [38]. However, H2O2
has been shown to be less effective than other peroxygens [41].
There was a marked difference betweentheefficacies oftwotypes of
peroxygens tested. The peracetic acid containing peroxygen was
active against all three PCR ribotypes, where the level of survival of
C. difficile was below the limit of detection for the assay, indicating a
5–Log10 reduction in spore titre, whereas the 012, 017 and 027
PCR-ribotypes were less susceptible to the potassium peroxymono-
sulphate containing peroxygen, with less than a 1-Log10 decrease in
spore titre at the recommended working concentration. However,
there were PCR-ribotype dependent differences in the susceptibility
to differing concentrations of VirkonH.
The CRAs ActichlorH and HaztabH showed a good efficacy at
5000 ppm and 1500 ppm, however, survival of spores was
detected for all three PCR-ribotypes at lower concentrations,
Figure 2. Exposure of C. difficile PCR-ribotype 012, 017 and 027 strains to disinfectants. Percentage survival after 30 minute exposure to
A) ActichlorH at 5000 ppm, 1500 ppm, 1000 ppm and 500 ppm. B) HaztabH at 5000 ppm, 1500 ppm, 1000 ppm and 500 ppm. C) PerasafeH at 2%,
1.62%, 1% and 0.81%. D) VirkonH at 2%, 1.5%, 1% and 0.5%. E) BiocleanseH at 20%, 10%, 5% and 2.5%. F) NewgennH at 0.8%, 0.4%, 0.2% and 0.1%.
G) Proceine 40H at 6%, 0.6% and 0.06%. H) Steri 7H at 100%, 80%, 40% and 20%. I) HibiscrubH at 50%. The survival was calculated as a percentage of
the heat resistant spore counts from unchallenged cultures. Data consists of three biological and two technical replicates from separate cultures.
,indicates survival was below the limit of detection of the assay (25 CFU/ml). Statistical analysis using linear regression (r
2) and an interaction test
(Chi
2) was performed using the statistical program Stata 12. Bracket ‘ indicate a significant difference in concentration independent of PCR-ribotype
(p,0.01), Bracket * indicates a significant difference between PCR-ribotypes independent of concentration (p,0.01) and Bracket ‘* indicates a
significant difference between PCR-ribotypes in a concentration dependent manor (p,0.01).
doi:10.1371/journal.pone.0025754.g002
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only sporicidal at high concentrations [42].
Under the experimental methodology used in this study, the
QACs were overall less effective against the three PCR-riboypes
than the CRAs and the peroxygens, which may be linked to their
use as mainly surfactants. However, interesting differences were
observed between these disinfectants that were dependent on
concentration and PCR-ribotype. The PCR ribotype 027 was
more susceptible to the majority of the QACs (except BiocleanseH)
and the peroxygen VirkonH than the 012 and 017 PCR-ribotypes.
However, the 027 PCR-ribotype was more resistant to the widely
used hand wash HibiscrubH than the 012 and 017 PCR-ribotypes.
All disinfectants exhibited effective inactivation of vegetative cells
at the majority of concentrations tested, with a few exceptions at
low concentrations.
The comparative efficacy of the nine disinfectants was assessed
using a Linear regression model controlling for strain (PCR-
ribotype), concentration and disinfectant, with ActichlorH as the
reference. The coefficient of variance was used as an estimate for
the relative efficacy of the disinfectants, with PerasafeH being the
most effective disinfectant under the experimental conditions used.
The global spread of CDI has seen the increase in other PCR
ribotypes such as 050 and 176 [43] which show a high level of
evolutionary similarity to 027 PCR-ribotypes [7]. Genetic and
evolutionary analysis of C. difficile revealed that it has a highly
dynamic genome, comprising gene loss, gene gain, rearrangements
and point mutations. The highly epidemic C. difficile lineages have
evolved independently; therefore the hypervirulent 027, 017 and
012 clades are genetically distinct [7]. This may account for the
differences observed in susceptibility to disinfectants. The
independent evolution is apparent with the acquisition of
fluoroquinolone resistance; one clade of the 027 lineage contains
a mutation in gyrB, which encodes intrinsic resistance to
fluoroquinolones. This genetic and evolutionary link may also be
the case for resistance to disinfectants. The genome sequence of
R20291 has revealed a number of efflux pumps and ABC
transporters unique to this hypervirulent 027 PCR-ribotype [44],
which may play a role in resistance to biocides.
Materials and Methods
Bacterial culture and media
C. difficile strains tested are as follows: R20291 a PCR-ribotype
027 from an outbreak at the Stoke Mandeville hospital, England,
2006, strain M68 a PCR-ribotype 017 from an outbreak in
Dublin, Ireland 2006 and strain 630 a PCR-ribotype 012 isolated
from a patient in Zurich, Switzerland 1982. These strains have
been genetically and phenotypically characterized and are good
representatives of their distinct lineages. Strains were stored at
280uC and cultured on C.C.E.Y Agar (Oxoid), supplemented
with 4% egg yolk emulsion (Bioconnections), 1% defibrinated
horse blood (TCS Biosciences), and cycloserine/cefoxitin antibi-
otic supplement (Bioconnections) for 1 to 2 days under anaerobic
conditions, in a Modular Atmosphere Control System 500 (Don
Whitney Scientific) at 37uC. All cultures were performed in
duplicate. Primary liquid cultures were inoculated with three
single colonies into 10 ml of pre-reduced Yeast Peptone (YP) broth
(16 g/L Peptone, 8 g/L Yeast, 5 g/L NaCl2) with 0.2% (v/v)
Tween 80 and incubated anaerobically for 24 hours on a shaking
platform at 60 rpm. Secondary cultures were inoculated using 1/
20 dilution of the primary cultures onto 40 ml of pre-reduced YP
broth with 0.2% (v/v) Tween 80 and incubated anaerobically for
24 hours.
Vegetative cells and spore counts
Vegetative cell counts were determined for all cultures, 1 ml of
each duplicate culture was centrifuged at 8000 x g and washed
with 1 ml of sterile phosphate buffered saline 1 x (PBS, Sigma),
samples were centrifuged again and pellets were resuspended in
1 ml PBS, serially diluted in 1 x PBS and plated in duplicate onto
blood agar base plates supplemented 7% (v/v) defibrinated horse
blood (TCS) and 0.1% (w/v) taurocholate (Sigma). Bacterial
counts were enumerated on plates after 24 hours and calculations
were performed to give colony forming units per ml (CFU/ml).
Heat resistant spore counts: 1 ml of each duplicate culture was
incubated at 56uC for 20 minutes to heat inactivate the vegetative
cells. The heat resistant spores were then centrifuged and washed
Table 2. Chi
2 and partial F-test p-vales.
Disinfectant Chi
2 p-value Partial F-test p-value
ActichlorH 0.0004 0.0172*
BiocleanseH 0.0017 0.0000
HaztabH 0.0004 0.0164*
HibiscrubH n/a 0.0050‘;
NewgennH 0.5131* 0.0000
PerasafeH n/a n/a
Prociene 40H 0.0610* 0.0000
Steri7H 0.0000 0.0026
VirkonH 0.0306* 0.0000
Chi
2 p-value is the probability that the differences observed for each
disinfectant are independent of strain and concentration, p,0.01 indicates that
strain and concentration are both a factor in the efficacy of the disinfectant,
whereas *indicates there is no significant interaction between strain and
concentration. A partial F-test was performed to determine whether there were
significant differences between the three PCR-ribotypes (p,0.01). ‘ indicates
the exception to the partial F-test, where the strain difference for Hibiscrub was
tested using a three variant Chi
2.
doi:10.1371/journal.pone.0025754.t002
Table 3. Disinfectant efficacy estimated using coefficient of
variance.
Disinfectant coefficient of variance p-value Standard error
PerasafeH 23.3024 0.000 0.296
ActichlorH 0 n/a 0.194
HaztabH 0.19 0.249 * 0.165
BiocleanseH 1.7004 0.000 0.358
NewgennH 2.415 0.000 0.318
Steri7H 2.64 0.000 0.275
VirkonH 2.974 0.000 0.369
Prociene 40H 3.4749 0.000 0.267
HibiscrubH 4.0972 0.000 0.292
A Linear regression was performed taking strain, concentration and disinfectant
into consideration. ActichlorH was used as the reference and the output gave
the coefficient of variance from the reference (p,0.01). This was then
normalised to the reference to give the overall variance from ActichlorH The
larger the negative coefficient of variance the higher efficacy of the disinfectant.
The standard error and p-values are listed, where *indicates no significant
difference from the reference ActichlorH (p.0.01).
doi:10.1371/journal.pone.0025754.t003
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in duplicate onto blood agar base plates supplemented 7% (v/v)
defibrinated horse blood (TCS Biosciences) and 0.1% (w/v)
taurocholate (Sigma). Colony counts were enumerated on plates
after 24 hours, and calculations were performed to give CFU/ml.
Direct spore countes were also made from the liquid culture using
a haemocytometer (Neubauer-ruled Bright Line counting cham-
bers; Hausser Scientific) and a light microscope (Nikon) at 1000 x
magnification.
Disinfectant assays
The disinfectants used in the study and concentrations are
described in Table 1. Disinfectant survival assays were performed
by mixing 1 ml of each duplicate culture with 1 ml of disinfectant
at the appropriate concentration to give the desired final
concentration. These were incubated for 30 minutes before 1 ml
of the samples was centrifuged, washed, serially diluted and plated
as outlined above. CFU counts were plotted in Graphpad Prism
(v4) as percentage survival compared to heat resistant spore
counts, error bars are standard error of the mean (SEM). The limit
of detection for the assay is 25 CFU/ml.
Statistical analysis
For the comparison between total counts and spore counts, an
unpaired two-tailed Students T-tests were performed in Graphpad
Prism (v4), with a confidence interval of 95% (p,0.05). Analysis on
the percentage spore production and the efficacy of the
disinfectants was performed using Stata 12 statistical analysis
program. Three questions were set to analyze the data i) is there a
strain dependent sensitivity to the disinfectants? ii) if so, what is the
most appropriate concentration to use? iii) which disinfectant has
the greatest efficacy across all three PCR-ribotypes and concen-
trations? Hypotheses i and ii were answered using an interaction
test (Chi
2) performed on two Linear regression analyses (r
2) using
log10 percentage survival data: The linear regression analyses
performed were a) the regression accounting for concentration
(independent of strain) and b) the regression accounting for both
strain (PCR-ribotype) and concentration. The Chi
2 test to look for
a relationship between strain and concentration was then
performed on these two regression data sets (a and b), where a
P,0.05 indicates that both strain (PCR-ribotype) and concentra-
tion are a factor in the efficacy of the disinfectant (Table 2). A
partial F-test was performed to determine whether there was a
significant difference between the PCR-ribotypes for each disinfec-
tant at a confidence interval of 99% (p,0.001) (Table 2). When
both the Chi
2 interaction test (p,0.05) and partial F-test (P,0.01)
gave significant difference between strain and concentration, the
most appropriate concentration for a particular ribotype could be
estimated. These estimates were calculated from the regression b
(strain and concentration) using the coefficient of variance from the
lowest concentration of a particular disinfectant. The lowest value
or largest negative coefficient of variance from the control (lowest
concentration) the more effective the disinfectant (Table S1),
whereas the more positive the coefficient of variance the less
effective the disinfectant under the test conditions (Table 3).
Hypothesis iii was addressed using a linear regression controlling
for strain, concentration and disinfectant, where the relative efficacy
of the nine disinfectants was assessed using the coefficient of
variance from ActichlorH the reference disinfectant. The largest
negative coefficient of variance from the control (0) the more
effective the disinfectant (Table 3), whereas the more positive the
coefficient of variance the less effective the disinfectant under the
test conditions (Table 3).
Supporting Information
Table S1 Concentration differences between PCR-ribo-
types. Where an interaction was detected by Linear regression
taking strain and concentration into consideration. The lowest
concentrationwas used as the reference for each disinfectant and
the output gave the coefficient of variance from the reference
(p,0.01). The larger the negative coefficient of variance the higher
efficacy of the disinfectant.
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